会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 1. 发明公开
    • Method for non-invasive diagnosis of transplantations and transfusions
    • Verfahren zur nicht-invasiven诊断von移植和输血
    • EP1325963A1
    • 2003-07-09
    • EP01811266.4
    • 2001-12-24
    • Holzgreve, Wolfgang, Prof.Hahn, Sinueh, Dr.GARRITSEN, Hendrikus, Stephanus, Paulus
    • Holzgreve, Wolfgang, Prof.Hahn, Sinueh, Dr.GARRITSEN, Hendrikus, Stephanus, Paulus
    • C12Q1/68
    • C12Q1/6881C12Q2600/156
    • It is known that rejection of transplant tissue is accompanied by tissue damage of the donor graft. Apart from donor specific proteins and genomic DNA, it is known, that by tissue damage mitochondrial DNA (mtDNA) will be released into the circulation of the recipient. Based on this knowledge it is the object of the present invention to suggest a new method or process to measure the quantity of cell free circulatory mtDNA in bodily fluids as an indicator or marker of tissue damage and to use mtDNA polymorphisms to discriminate between donor and recipient tissue damage in a transplant setting. The method according to the invention is a non-invasive diagnostic procedure characterised by the following steps:

      A. Before transplantation
         d) Obtaining mtDNA containing material from donor and recipient before transplantation.
         e) Isolation of mtDNA.
         f) Analysing of the hypervariable regions of the mtDNA for informative polymorphisms which can discriminate between donor and recipient.
      B. After Transplantation
         c) Obtaining cell free bodily fluids from a patient.
         d) Mitochondrial DNA extraction using a commercial procedure. Detection and quantification of donor specific mtDNA in the probe of patient using the donor specific polymorphisms.
    • 已知移植组织的排斥伴随供体移植物的组织损伤。 除了供体特异性蛋白质和基因组DNA之外,已知通过组织损伤线粒体DNA(mtDNA)将被释放到受体的循环中。 基于这些知识,本发明的目的是提出一种测量体液中无细胞循环mtDNA的量作为组织损伤指标或标志物的新方法或方法,并使用mtDNA多态性来区分给体和受体 组织损伤在移植设置。 根据本发明的方法是非侵入性诊断程序,其特征在于以下步骤:A.移植前d)在移植前从供体和受体获得含有mtDNA的物质。 e)mtDNA的分离 f)分析可以区分供体和受体的信息多态性的mtDNA的高变区。 B.移植后c)从患者获得无细胞的体液。 d)使用商业程序进行线粒体DNA提取。 使用供体特异性多态性检测和定量患者探针中供体特异性mtDNA。
    • 2. 发明公开
    • Method for the non-invasive prenatal diagnosis of chromosomal and/or genetic abnormalities
    • 方法zur non invasiven prenatalen诊断染色体und / oder遗传学Abnormalitäten
    • EP1329517A1
    • 2003-07-23
    • EP02405033.8
    • 2002-01-22
    • Holzgreve, Wolfgang, Prof.Hahn, Sinueh, Dr.Zimmermann, Bernard
    • Holzgreve, Wolfgang, Prof.Hahn, Sinueh, Dr.Zimmermann, Bernard
    • C12Q1/68
    • C12Q1/6883C12Q1/6827C12Q1/6851C12Q1/6858C12Q2600/156C12Q2600/16C12Q2561/113C12Q2545/101C12Q2535/125
    • The detection of gross chromosomal abnormalities is a major focus of invasive prenatal diagnosis testing. The object of the present invention is to suggest a new method for the diagnosis of chromosomal and/or genetic abnormalities that is readily amenable to automation and high-throughput screening. This stated object of the invention is achieved by a method, characterised by the following steps:

      obtaining DNA or RNA with the genetic test locus,
      obtaining DNA or RNA of a control locus and
      detecting of the chromosomal and/or genetically determined abnormalities by Real-Time Polymerase Chain Reaction (RT-PCR) analysis, which detects specific nucleic acid amplification products as they accumulate in real-time.
      In particular the method is further characterised by a multiplex RT-PCR assay in which amplification of both loci can been simultaneously monitored in the same reaction vessel, by a fluorescently labeled oligonucleotide probe, which eliminates the need for post-PCR processing. It is a preferred object of the invention to provide the method for the detection of trisomy 21 and in this way sequence specific primers for this specific analysis has been designed.
    • 染色体总体异常检测是侵入性产前诊断检测的重点。 本发明的目的是提出一种用于诊断易于自动化和高通量筛选的染色体和/或遗传异常的新方法。 本发明的上述目的通过一种方法实现,其特征在于以下步骤:用遗传测试基因座获得DNA或RNA,获得对照基因座的DNA或RNA,并通过Real-time检测染色体和/或遗传上确定的异常, 时间聚合酶链反应(RT-PCR)分析,检测特定的核酸扩增产物,因为它们实时积累。 特别地,该方法的特征还在于通过多重RT-PCR测定法,其中可以通过荧光标记的寡核苷酸探针在同一反应容器中同时监测两个位点的扩增,从而不需要PCR后处理。 本发明的优选目的是提供用于检测21三体的方法,并且以这种方式设计了该特定分析的序列特异性引物。
    • 4. 发明公开
    • Non-invasive detection of fetal genetic traits
    • Nicht invasiver Nachweisfötalergenetischer Merkmale
    • EP1524321A1
    • 2005-04-20
    • EP03405742.2
    • 2003-10-16
    • Hahn, Sinuhe, Dr.Zimmermann, BernhardHolzgreve, Wolfgang, Prof.Li, Ying
    • Hahn, Sinuhe, Dr.Zimmermann, BernhardHolzgreve, Wolfgang, Prof.Li, Ying
    • C12Q1/68
    • C12Q1/6883C12Q1/6806C12Q2600/156C12Q2565/125
    • Blood plasma of a pregnant woman contains both fetal and maternal circulatory extracellular DNA, the latter forming the major part (generally > 90%) thereof. The majority of the circulatory extracellular fetal DNA has now been found to have a small size of approximately 500 base pairs or less whereas the majority of the circulatory extracellular maternal DNA has a size greater than approximately 500 base pairs. Separation of circulatory extracellular DNA fragments which are smaller than approximately 500 base pairs provides a possibility to enrich for fetal DNA sequences from the vast bulk of circulatory extracellular maternal DNA.
      There is thus provided a sample of the blood plasma or serum (which preferably is substantially cell-free) of a pregnant woman in which extracellular DNA comprising 500 base pairs or less is enriched; the manufacture of such sample by subjecting a sample of the blood plasma or serum of a pregnant woman to a size separation so as to enrich extracellular DNA comprising 500 base pairs or less; and the use of such sample for the non-invasive detection of fetal genetic traits.
    • 孕妇的血浆含有胎儿和母体的循环细胞外DNA,后者形成主要部分(通常> 90%)。 现在已经发现大多数循环细胞外胎儿DNA具有约500个碱基对或更小的小尺寸,而大多数循环细胞外母体DNA具有大于约500个碱基对的大小。 小于约500碱基对的循环细胞外DNA片段的分离提供了从大量循环细胞外母体DNA中丰富胎儿DNA序列的可能性。 因此,提供了富含500碱基对或更少的胞外DNA的孕妇血浆或血清(优选基本上不含细胞)的样品; 通过对怀孕妇女的血浆或血清样品进行大小分离以富集包含500个碱基对或更少的细胞外DNA的方式制备这种样品; 以及使用这种样品进行胎儿遗传性状的非侵入性检测。